Under construction – not a live service
Sign in
Taking peopleNo phase

Blood Test Study Using AI to Detect Cancer Early and Track Treatment

Tests an AI-based blood test in adults with several cancers, including breast and lung.

Plain-language title generated from the registry record
Registry title: The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling

Key facts

Where
Rosario, ArgentinaSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 40 and 75 years old?

Source: NCT06717295, who can take part

Where in Argentina

  • Various Cancer CentresRosario, ArgentinaNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Javier Toledo
Trial code
NCT06717295
Record updated
2 January 2026
Original description
The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients. This two-phase, multi-center observational study aims to identify specific transcriptomic biomarkers in platelets and immune cells that distinguish cancer patients from healthy individuals and correlate with treatment outcomes. By analysing blood samples using artificial intelligence, the study seeks to create a safe, non-invasive method to enhance cancer diagnosis and monitor treatment responses over time.Read full original descriptionShow less

The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cell Transcriptomic Profiling

The purpose of the CCANED-CIPHER study is to develop and validate an AI-based blood test for early cancer detection and to monitor treatment effectiveness in cancer patients. This two-phase, multi-center observational study aims to identify specific transcriptomic biomarkers in platelets and immune cells that distinguish cancer patients from healthy individuals and correlate with treatment outcomes. By analysing blood samples using artificial intelligence, the study seeks to create a safe, non-invasive method to enhance cancer diagnosis and monitor treatment responses over time.

Inclusion: Age: Adults aged 40 years or older; Confirmed diagnosis of one of the following common cancers: Non-Small Cell Lung Cancer (NSCLC), Glioblastoma Multiforme (GBM), Colorectal Cancer, Hepatocellular Carcinoma (HCC), Breast Cancer, Prostate Cancer, Ovarian Cancer, Pancreatic Cancer; Adults aged 40 years or older; Confirmed diagnosis of: Hepatocellular Carcinoma (HCC), Non-Small Cell Lung Cancer (NSCLC); Willingness to provide blood samples at the specified intervals (baseline, 6 weeks, and 6 months post-therapy initiation).

Exclusion: Use of anticoagulant or antiplatelet drugs within the past 2 weeks; Presence of any active infectious diseases; Any medical or psychological conditions that may affect the participant's ability to comply with study procedures; Phase 2 ( Cancer Immuno-Profiling of Hematologic and Extracellular RNA - CIPHER); Presence of another malignancy unless it has been in remission for at least 5 years; Significant uncontrolled co-morbid conditions that may interfere with study participation or outcomes; Currently pregnant.

Phase 1 (Common Cancer Early Detection - CCANED).

ClinicalTrials.gov NCT06717295